Heart Team first
Current valve guidance places patient-centered Heart Team assessment and experienced valve-center care at the center of treatment choice.
TAVR cost in Turkey
TAVR or TAVI pricing is driven mainly by the transcatheter valve, but a safe estimate must also include gated CT sizing, coronary and vascular assessment, hybrid-lab resources, anesthesia strategy, surgical rescue, rhythm monitoring, and a written plan if vascular injury, leak, stroke, kidney injury, or permanent pacemaker need extends care.
How much does TAVR cost in Turkey?
For international patients, planned transfemoral TAVR in Turkey is commonly budgeted at TRY 705,000 to 1,175,000 (about USD 15,000 to 25,000). Alternative access, valve-in-valve work, uncommon sizing, complex coronary protection, intensive care, an added pacemaker, or complication treatment can raise the total above TRY 1,410,000 (about USD 30,000).
USD illustrations use about TRY 47 per USD, close to the official indicative selling rate on 17 July 2026. Imported valves may be quoted in EUR or USD; confirm device validity, controlling currency, deposit, cancellation, and unused-device refund rules.
Share the basics and the Virello team will guide you toward the next step.
Prefer email? Write to support@virellohealth.com.
Reviewed 2026-07-19
Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team
Billing context: TRY and USD
Current valve guidance places patient-centered Heart Team assessment and experienced valve-center care at the center of treatment choice.
Annulus, calcium, coronary height, root, and access-vessel measurements determine feasibility, valve sizing, and risk.
Conduction disturbance can require longer monitoring or permanent pacemaker implantation, with separate device and admission costs.
Age, life expectancy, future coronary access, surgical options, and possible valve-in-valve treatment belong in the decision.
Cost at a glance
The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.
| Scenario | TRY | USD | Patient and treatment context | Planning scope |
|---|---|---|---|---|
| Routine transfemoral TAVR | TRY 705,000 - 940,000 | USD 15,000 - 20,000 | Severe aortic stenosis with suitable annulus and access vessels, standard valve size, and predictable monitored recovery. | Should name valve platform, CT, cath or hybrid lab, team, stated stay, routine echo, and discharge review. |
| Complex sizing or coronary planning | TRY 940,000 - 1,175,000 | USD 20,000 - 25,000 | Small or large annulus, low coronary height, heavy calcium, difficult access, prior valve, or need for protection techniques. | Requires device-specific planning, additional equipment, and a clear rescue budget. |
| Alternative access or complication pathway | TRY 1,175,000 - 1,410,000+ | USD 25,000 - 30,000+ | Non-femoral access, urgent instability, vascular repair, stroke care, dialysis, permanent pacing, or conversion to surgery. | Cannot be promised as a fixed routine package. |
Usually included
Named platform and size or a defined device allowance.
Ask how size or model changes price.
Interventional cardiology, cardiac surgery, anesthesia, imaging, cath-lab team, and routine monitoring.
Confirm surgical rescue is on site.
Specified CT, laboratory work, procedure, ICU or monitored bed, ward days, echo, and discharge review.
Obtain overstay rates.
Valve card, procedure note, imaging, discharge summary, and medicine plan.
Keep records for lifelong follow-up.
Confirm separately
PCI, coronary protection devices, lithotripsy, vascular stents, surgical repair, or alternative access.
Price expected adjuncts before travel.
Generator, leads or leadless device, electrophysiology service, and added stay.
Ask for a scenario price.
Stroke, bleeding, kidney injury, tamponade, valve embolization, severe leak, surgery, or prolonged ICU.
Clarify authorization and billing.
Flights, accommodation, repeat echo, medicines, dental prevention, and home cardiology.
Budget beyond discharge.
Candidate context
TAVR may be considered for severe symptomatic aortic stenosis and selected other aortic-valve situations after integrating age, anatomy, surgical risk, life expectancy, frailty, coronary disease, access, valve durability, and preference. It is not automatically the best choice because it avoids sternotomy. Surgical replacement can be more appropriate for younger patients, bicuspid or aortic-root disease, unfavorable access, endocarditis, or combined coronary and valve needs.
Echo severity, symptoms, ventricular function, flow state, and sometimes invasive data must agree sufficiently to justify intervention.
Annulus, calcium distribution, coronary height, sinus dimensions, root, aorta, and iliofemoral vessels shape device and access.
Frailty, kidney and lung disease, stroke history, bleeding, cognition, infection, mobility, and expected benefit affect candidacy.
Future coronary access, pacemaker risk, valve durability, possible redo TAVR, and surgery feasibility should be discussed.
SAVR may better suit younger, lower-risk, bicuspid, aortic-root, endocarditis, or combined-operation cases.
When disease is not yet severe or intervention is unlikely to improve meaningful survival or quality of life, another strategy may be advised.
This may occasionally bridge an unstable or time-sensitive situation but is not a durable substitute for valve replacement.
Procedure variations
Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.
Valve delivery through suitable leg arteries and usually the preferred access when feasible.
CT must confirm vessel size and disease.
Another arterial or surgical route may be used when femoral access is unsafe.
Technique, anesthesia, stay, and cost differ.
A transcatheter valve may treat selected failing surgical bioprostheses.
Internal diameter and coronary obstruction risk are crucial.
Selected anatomy may prompt additional devices and techniques.
Ask for evidence, availability, and price.
City comparison
Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.
| City | Local range | USD range | Capability context | Stay planning |
|---|---|---|---|---|
| Istanbul | TRY 799,000 - 1,316,000 | USD 17,000 - 28,000 | Broadest structural-heart and device choice. | Compare exact valve and premium-hospital costs. |
| Ankara | TRY 752,000 - 1,269,000 | USD 16,000 - 27,000 | Advanced academic and tertiary programs. | Confirm international tariff and access route. |
| Izmir | TRY 705,000 - 1,175,000 | USD 15,000 - 25,000 | Selected established structural-heart programs. | Verify current valve inventory. |
| Antalya | TRY 752,000 - 1,222,000 | USD 16,000 - 26,000 | International coordination with limited program choices. | Validate surgical rescue on site. |
| Bursa | TRY 681,500 - 1,128,000 | USD 14,500 - 24,000 | Selected tertiary valve capability. | Ask about CT and electrophysiology support. |
| Kocaeli and Gebze | TRY 705,000 - 1,175,000 | USD 15,000 - 25,000 | Marmara-region tertiary access. | Budget airport transfers. |
| Adana | TRY 681,500 - 1,128,000 | USD 14,500 - 24,000 | Selected regional tertiary programs. | Confirm device sizing availability. |
| Konya | TRY 658,000 - 1,081,000 | USD 14,000 - 23,000 | Potential value only where full Heart Team capability is documented. | Do not accept remote surgical backup. |
| Kayseri | TRY 658,000 - 1,081,000 | USD 14,000 - 23,000 | Case-specific tertiary availability. | Review flight and follow-up logistics. |
| Gaziantep | TRY 634,500 - 1,034,000 | USD 13,500 - 22,000 | Hospital-level validation is essential. | Request named team and valve platform. |
Estimate variables
Imported device procurement dominates cost.
Name model, size range, and currency.
Difficult vessels, calcium, coronary risk, or prior valve add equipment and time.
Use CT-led pricing.
Monitoring or pacemaker implantation increases stay and device cost.
Get a separate scenario.
Surgery, vascular repair, stroke care, dialysis, and ICU support alter exposure.
Capability comes before price.
Medical cost breakdown
Complete severity and ventricular assessment.
Provide source images.
Annulus, root, coronary, aorta, and access mapping.
Kidney function affects contrast planning.
Coronary imaging plus functional, dental, infection, anesthesia, and laboratory assessment.
Resolve treatment sequencing.
Prosthesis, delivery system, hybrid room, imaging, and team.
Confirm backup valve policy.
Rhythm, access, neurologic, kidney, and valve surveillance.
Day limits matter.
Pacemaker, PCI, vascular repair, or ICU escalation.
Usually separate.
Checks valve function, leak, conduction, and symptoms.
Complete before travel.
Antithrombotic and cardiac medicines are individualized.
Do not self-adjust.
Cardiology, echo, dental prevention, and urgent warning-sign access.
Arrange before departure.
Complete journey budget
Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.
Flights and assistance suited to age and mobility.
Allow changed return dates.
Nearby lodging and local transfers.
Avoid long commutes.
Extra monitoring, pacemaker, medicines, or delayed flight.
Keep a substantial reserve.
Country access
Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.
Check the Ministry international-health-tourism list and the named hospital’s current structural-heart service.
Check e-Visa eligibility or consular requirements before non-refundable payment.
Take the valve card, serial details, procedure note, CT, echo, ECG, discharge summary, and itemized invoice.
Use labeled packages, prescriptions, and an adequate supply for delays.
Hospital selection
TAVR, surgical valve, CT, echo, coronary, vascular, rhythm, and intensive-care services.
All should work as one team.
Approved valves, sizing, traceability, backup inventory, and transparent substitution.
Document the implanted model.
On-site cardiac surgery, perfusion, vascular repair, stroke response, dialysis, and blood bank.
Ask about 24-hour readiness.
Program experience with mortality, stroke, vascular injury, leak, and pacemaker using defined time periods.
Avoid unqualified success claims.
Treating team
Leads catheter implantation and device strategy.
Assesses SAVR and provides procedural and rescue expertise.
Integrates echo and CT sizing, access, and coronary risk.
Supports sedation, hemodynamics, conduction monitoring, and complications.
Treatment timeline
Echo, CT if available, coronary records, labs, symptoms, frailty, medicines, and surgical history are reviewed.
Repeat targeted tests and confirm TAVR versus surgery, valve, access, and rescue plan.
Access, valve deployment, imaging confirmation, closure, and immediate rhythm and neurologic checks occur.
The team follows conduction, access, kidney, mobility, and valve function.
Home cardiology receives device, imaging, medicine, surveillance, and warning-sign records.
Risks and edge cases
May need transfusion, covered stent, surgery, or longer care.
Price rescue separately.
Requires immediate neurologic treatment and changes travel.
Verify stroke pathway.
Temporary monitoring or permanent pacing may be required.
Ask for device cost.
May require another valve, intervention, support, or surgery.
Confirm backup inventory.
Contrast and hemodynamic changes can impair renal function.
Plan hydration and dialysis backup.
Destination comparison
The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.
| Decision factor | India | Turkey | Thailand | How to use this |
|---|---|---|---|---|
| Device and team access | Growing TAVR availability in leading cardiac centers. | Strong programs in major tertiary cities with imported valve pricing. | Advanced structural care mainly in top Bangkok hospitals. | Compare exact valve, Heart Team, and rescue depth. |
| Quote currency | INR or USD is common. | TRY, EUR, or USD may control imported-device billing. | THB packages may itemize device and room. | Use one comparable scope and conversion date. |
| Travel fit | Practical for South Asia, Gulf, and parts of Africa. | Practical for Europe and nearby regions. | Practical for Southeast Asia. | Age, mobility, companion, and urgent follow-up matter. |
Decision guidance
A current program reviews CT, offers both surgical and catheter expertise, names the valve, and documents rescue and follow-up.
The quote precedes CT review, omits device identity or pacemaker pricing, or surgical backup is unclear.
Fainting, resting breathlessness, chest pain, shock, or rapid deterioration occurs.
Reports for review
TAVR decisions require original echo and CT data, not a short diagnosis label. Include coronary imaging, prior valve records, kidney function, rhythm history, frailty and mobility, dental or infection concerns, medicines, allergies, and the patient’s treatment goals.
Upload medical reportsProvide the complete echo images and report as a readable record for clinical and cost review.
Provide the complete gated tavr ct source files as a readable record for clinical and cost review.
Provide the complete prior valve implant card as a readable record for clinical and cost review.
Provide the complete serial valve studies as a readable record for clinical and cost review.
Provide the complete coronary angiography or ct as a readable record for clinical and cost review.
Provide the complete ecg and rhythm monitor as a readable record for clinical and cost review.
Provide the complete vascular imaging as a readable record for clinical and cost review.
Provide the complete prior cardiac operation notes as a readable record for clinical and cost review.
Provide the complete kidney and blood tests as a readable record for clinical and cost review.
Provide the complete symptoms, frailty, mobility, cognition as a readable record for clinical and cost review.
Provide the complete medicines, bleeding, allergies as a readable record for clinical and cost review.
Provide the complete passport and companion details as a readable record for clinical and cost review.
Common questions
The estimate should name a platform or allowance and explain sizing, substitutions, backup devices, and currency.
Only provisionally. CT sizing and access analysis are central to feasibility, device selection, and risk.
Yes. Conduction disturbance is a known risk; request a separate pacemaker and added-stay scenario.
Risk depends on patient and anatomy. Heart Team assessment should compare both options and lifetime strategy.
Uncomplicated stays may be short, but rhythm, access, kidney, neurologic, or mobility issues can extend care.
Valve-in-valve may be possible after implant sizing and coronary-risk review.
An alternative access or surgery may be discussed, changing technique, risk, stay, and cost.
Only after individualized review of rhythm, access, mobility, symptoms, complications, and airline requirements.
The signed quote must say whether TRY, EUR, or USD governs the valve and final invoice.
Carry valve card, procedure note, CT and echo, ECG, discharge summary, medicines, and surveillance schedule.
Review and sources
The range separates routine transfemoral treatment from complex sizing, alternative access, valve-in-valve, and complication pathways. Device-led Turkey price signals were normalized near the 17 July 2026 rate; current valve guidance shaped candidacy and hospital checks. Only a CT-led, time-limited hospital quotation can set an individual cost.
This guide cannot diagnose aortic stenosis, choose TAVR over surgery, select a valve, prescribe medicines, or clear travel. Obtain Heart Team review and a signed estimate. Fainting, chest pain, resting breathlessness, low blood pressure, or rapid decline requires urgent local care.
European Society of Cardiology · Accessed 2026-07-19
Supports: Heart Team, valve centers, TAVI, surgery, and imaging.
European Society of Cardiology · Accessed 2026-07-19
Supports: Current intervention and treated-valve priorities.
Republic of Turkey Ministry of Health · Accessed 2026-07-19
Supports: International service rules.
Republic of Turkey Ministry of Health · Accessed 2026-07-19
Supports: Provider checks.
Republic of Turkey Ministry of Foreign Affairs · Accessed 2026-07-19
Supports: Entry checking.
Central Bank of the Republic of Turkey via e-Government Gateway · Accessed 2026-07-19
Supports: Conversion context.
Related planning
Compare surgical replacement.
Plan conduction-device scenarios.
Review coronary surgery.
Compare another destination.
Understand candidacy and recovery.
Compare structural-heart capability.
Review surgical expertise.
Prepare imaging.
Compare valve recommendations.
Request itemized pricing.
Questions about an estimate? Email support@virellohealth.com.